Clinical effects of Cariprazine and their relationship with polymorphisms of dopamine and serotonin receptors: preliminary results from a prospective study on schizophrenia and bipolar disorder

INTRODUCTION: Cariprazine (CAR) is a D2, D3, 5HT1A receptor partial agonist and a 5HT2A, 5HT2B antagonist, used to treat Schizophrenia and Bipolar disorder. Interindividual variability in therapeutic and side effects of antipsychotics is difficult to predict, due to non-genetic and genetic factors....

Descripción completa

Detalles Bibliográficos
Autores principales: De Pieri, M., Dyrmishi, E., Bolla, E., Preve, M., Colombo, R.A., Traber, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9566989/
http://dx.doi.org/10.1192/j.eurpsy.2022.1746

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9566989/
http://dx.doi.org/10.1192/j.eurpsy.2022.1746

Ejemplares similares